Adial Pharmaceuticals
ADIL
14 hedge funds and large institutions have $491K invested in Adial Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 0 closing their positions.
210% more capital invested
Capital invested by funds: $158K → $491K (+$333K)
75% more funds holding
Funds holding: 8 → 14 (+6)
0.68% more ownership
Funds ownership: 0.19% → 0.87% (+0.68%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$349K |
| 2 |
Renaissance Technologies
New York
|
+$50.9K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$32.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.26K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$6.74K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Armistice Capital
New York
| $296K | +$349K | +6,360 | New |
|
|
MCM
2
Manchester Capital Management
Manchester,
Vermont
| $89.5K | – | – | – |
|
|
3
Renaissance Technologies
New York
| $43K | +$50.9K | +928 | New |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $27.5K | +$32.4K | +592 | New |
|
5
BlackRock
New York
| $14.2K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $7.88K | +$9.26K | +169 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $6.74K | +$6.74K | +123 | +559% |
|
8
JP Morgan Chase
New York
| $4.65K | +$5.48K | +100 | New |
|
9
Osaic Holdings
Scottsdale,
Arizona
| $1.15K | – | – | – |
|
|
FWM
10
Focused Wealth Management
Newburgh,
New York
| $1.02K | +$1.21K | +22 | New |
|
|
AWM
11
Abound Wealth Management
Franklin,
Tennessee
| $51 | – | – | – |
|
12
Morgan Stanley
New York
| $34 | – | – | – |
|
13
Qube Research & Technologies (QRT)
London,
United Kingdom
| $15 | – | – | – |
|
14
Wells Fargo
San Francisco,
California
| $15 | – | – | – |
|
ADIL Hedge Fund Activity: Q4 2023 in Review
14 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q4 2023, worth a combined $491K — up 210% from $158K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ADIL positions and 0 closed out — a net gain of 6 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $349K.
- 14 institutional investors held Adial Pharmaceuticals (ADIL) as of Q4 2023, up from 8 in Q3 2023.
- Funds reported $491K of Adial Pharmaceuticals stock for Q4 2023, up 210% quarter-over-quarter.
- 6 funds opened new Adial Pharmaceuticals positions in Q4 2023 and 0 closed out, a net change of +6 holders.
- The largest Adial Pharmaceuticals buyer in Q4 2023 was Armistice Capital, an estimated $349K added.
Based on aggregated 13F filings for Q4 2023.